New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:31 EDTDEPODepomed files patent infringement suit against Purdue Pharma
Depomed disclosed in a regulatory filing that on January 29, Depomed filed a complaint in the United States District Court for the District of New Jersey against Purdue Pharma and affiliated companies for infringement of U.S. Patent Nos. 6,340,475; 6,635,280; and 6,723,340. The complaint alleges infringement of the Depomed patents arising from Purdue’s commercialization of OxyContin in the United States. The Depomed patents relate to Depomed’s Acuform drug delivery technology. U.S. Patent Nos. 6,340,475 and 6,635,280 will expire in 2016, and U.S. Patent No. 6,723,340 will expire in 2021.
News For DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
10:02 EDTDEPOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTDEPODepomed downgraded to Neutral at Janney Capital
Subscribe for More Information
08:16 EDTDEPODepomed downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
March 17, 2015
08:35 EDTDEPODepomed announces expiration of waiting period to acquire rights of NUCYNTA
Depomed announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use